The present study was aimed at investigating whether imatinib pharmacogenetics is related to its pharmacodynamics in patients affected by chronic myeloid leukemia.

Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia

FAVA, Carmen;D'AVOLIO, ANTONIO;SAGLIO, Giuseppe;
2017-01-01

Abstract

The present study was aimed at investigating whether imatinib pharmacogenetics is related to its pharmacodynamics in patients affected by chronic myeloid leukemia.
2017
79
4
767
773
ABCB1; Complete cytogenetic response; Factor analysis of mixed data; Imatinib; Tolerability; hOCT1
Galeotti, Laura; Ceccherini, Francesco; Domingo, Dario; Laurino, Marco; Polillo, Marialuisa; Di Paolo, Antonello; Baratè, Claudia; Fava, Carmen; D'Avolio, Antonio; Cervetti, Giulia; Guerrini, Francesca; Fontanelli, Giulia; Ciabatti, Elena; Grassi, Susanna; Arrigoni, Elena; Danesi, Romano; Petrini, Mario; Cornolti, Fulvio; Saglio, Giuseppe; Galimberti, Sara
File in questo prodotto:
File Dimensione Formato  
art%3A10.1007%2Fs00280-017-3271-3.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 688.66 kB
Formato Adobe PDF
688.66 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1635829
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 8
social impact